NEXT GENERATION FERTILITY TECH

Separating Winning
Sperm in Alliance
with Nature

ABOUT
Molecule 46

Molecule 46 is a biotech spin-off offering a unique patented technology for the separation of undamaged sperm to be used in human assisted reproduction and solve the infertility problem related to poor sperm quality.

This technology is equally applicable to animal breeding strategies. The company brings an innovative approach with a strong IP position and robust scientific research. The new technology and clear regulatory pathway are strengthened by an internationally recognised founder with a strong academic track record and founder/market fit for a large and fast-growing market.

This project offers real social impact as well as endorsement from buyers and users.

OUR SUCCESS

HUMAN
Application

ASSISTED REPRODUCTION
Increase of sperm quality
a fertilization success

CRYOPRESERVATION
Personalised approach
to oncology patients

ONCOFERTILITY
Personalised approach
to oncology patients

PREVENTIVE MEDICINE
Diagnostics and screening
of reproductive health

ANIMAL

Application

LIVESTOCK BREEDING
Healthy sperm for
efficient insemination

ENDANGERED SPECIES CONSERVATION
Undamaged sperm for
ZOO-based fertility programs

HUMAN
Application

ASSISTED
REPRODUCTION
Increase of sperm quality
a fertilization success

CRYOPRESERVATION
Personalised approach
to oncology patients

ONCOFERTILITY
Personalised approach
to oncology patients

PREVENTIVE MEDICINE
Diagnostics and screening
of reproductive health

ANIMAL

Application

LIVESTOCK BREEDING
Healthy sperm for
efficient insemination

ENDANGERED SPECIES
CONSERVATION
Undamaged sperm for
ZOO-based fertility
programs

SUCCESS to date

STRONG IP POSITION
AND PROACTIVE IP STRATEGY

  • Exclusive rights to core IP assets, new filings expected
  • Czech and European patents granted
  • FTO analyses performed once a year

SCIENTIFIC EVIDENCE
& PROOF-OF-MARKET

  • Technology backed by 15 years of research
  • In-vitro benchmarking studies completed
  • Two prototype iterations leading to MVP 2.0
  • Molecule 46 technology currently at level TRL 3
  • Endorsement by seven leading IVF clinics in the Czech Republic
  • Twenty more early adopter leads in the pipeline

LOCAL & INTERNATIONAL
NON-DILUTIVE FUNDING

  • Molecule 46 is financially supported by SIC and CzechInvest Technology Incubation
  • Additional applications under evaluation (€75k)
  • Pre-submission stage (€200k)

PEOPLE

  • Core R&D and business team members ready for onboarding
  • Advisory board to be completed in Q1 2025

MEDIA presentations

2024

Forbes, The most influential women
of the Czech Republic

Forbes, Invited speaker at The Next Big Thing

Nominated for The Czech Scientist
of the Year – Innovation Technology
and EY Entrepreneur of the Year

2022

The Guardian, The Telegraph, BBC Science focus, Daily Mirror, The Tribune, Yahoo news

Czech TV, Prima CNN, Czech Radio,
and newspaper coverage

Czech Grant agency award for outstanding grant achievement

2023

Forbes, Top Czech women scientist 2023

Ministry of Foreign Affairs, Czech women in World Science, TV and newspaper coverage, Czech Consulate, Istanbul, Turkey

2021

Czech Press Office release,
The utilization of CD46 protein can accelerate the process of artificial insemination.